BioSpace News Archive

BioCardia ® , Inc. NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 4,762,000 shares of common stock at a price to the public of $2.10 per share. BioCardia expects to receive gross proceeds of $10 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Bi

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that it has further accelerated its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. Willow is a Canadian biotechnology comp

The University of Phoenix College of Health Professions has announced a new Master of Public Health with a Concentration in Community Health Leadership.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the management team will participate in the following upcoming virtual investor conferences: Raymond James’ Human Health Innovation Conference - Presentation: Thursday, June 18, 2020 from 2:20-2:50 PM ET - Webcast

Clovis Oncology to Highlight Rubraca ® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020

Verve Therapeutics , a next-generation cardiovascular company developing medicines that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics, will give a keynote presentation on the genetic basis for risk and resistance to coronary heart disease and gene editing as a p

Spinal Elements, a Carlsbad, CA-based medical device company focused on spine surgery procedures, introduced its MIS Ultra™ platform of products and procedures.

Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers

Santen Pharmaceutical Co., Ltd. and Orbis International announced a partnership to develop a suite of digital training tools that will continue to help eye care professionals around the world build their skills.

AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.